289 filings
Page 11 of 15
8-K
sufyi ojujj3kdy4aqo
3 Feb 20
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
7:32am
8-K
bht104zcj8i9hbl 08nx
13 Jan 20
Regulation FD Disclosure
7:01am
8-K
gtb97yhjcedt3zs
19 Dec 19
Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models
4:06pm
8-K
szu16
4 Dec 19
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
7:31am
8-K
0p5d5n6ypy
19 Nov 19
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
7:33am
8-K
5ag194mv
12 Nov 19
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial
4:46pm
8-K
e0in62zkwbner8
12 Nov 19
Results of Operations and Financial Condition
6:33am
8-K
8vdkva1nd64snwpy
29 Oct 19
Regulation FD Disclosure
4:01pm
8-K
0hib84l7l7v7hlv33w
29 Oct 19
Data Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7:31am
8-K
2sbt00axc
22 Oct 19
Regulation FD Disclosure
7:32am
8-K
n1gftt3fw 8o6yv22r
16 Aug 19
Results of Operations and Financial Condition
5:18pm
8-K
tvbe5w54
13 Aug 19
Regulation FD Disclosure
7:34am
8-K
1qi1o 107nl8
6 Aug 19
Regulation FD Disclosure
7:48am
8-K
8z0dvohcmhv5wgtewqq
24 Jul 19
Entry into a Material Definitive Agreement
7:30am
8-K
1djz l3my9ghg9cz
18 Jul 19
Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort
4:02pm
8-K
ij3nag
12 Jul 19
Departure of Directors or Certain Officers
4:03pm
8-K
fwxlcccbcb
31 May 19
Regulation FD Disclosure
4:06pm
8-K
3q9r3490w1ourx
24 May 19
Amendments to Articles of Incorporation or Bylaws
4:09pm
8-K
0nll6yjcfhldwc9sg
14 May 19
Results of Operations and Financial Condition
7:31am
8-K
q3bbsszythwgo3
7 May 19
Regulation FD Disclosure
4:34pm